EyePoint (EYPT) Retained Earnings (2011 - 2026)
EyePoint (EYPT) posted Retained Earnings of -$1.2 billion for Q1 2026, down 7.68% sequentially from -$1.1 billion in Q4 2025, and down 29.58% YoY from -$1.7 billion in Q1 2025.
EyePoint (EYPT) Retained Earnings (2011 - 2026) Analysis & Trends
EyePoint has reported Retained Earnings for 16 years, with the latest figure at -$1.2 billion in Q1 2026.
- Quarterly Retained Earnings fell 29.58% year-over-year to -$1.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.2 billion (down 29.58% YoY) and the FY2025 annual result came in at -$1.1 billion, down 107588.13% from the prior year.
- Retained Earnings slipped to -$1.2 billion in Q1 2026 per EYPT's latest filing, from -$1.1 billion in the prior quarter.
- Over five years, Retained Earnings peaked at $1.2 million in Q3 2024 and troughed at -$1.2 billion in Q1 2026.
- A 5-year average of -$538.5 million and a median of -$692.5 million in 2023 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2023 and 2024: Retained Earnings sank 111592.65% in 2023, then soared 100.16% in 2024.
- Over 5 years, Retained Earnings stood at $786000.0 in 2022, then grew by 9.92% to $864000.0 in 2023, then grew by 18.98% to $1.0 million in 2024, then plunged by 107588.13% to -$1.1 billion in 2025, then slipped by 7.68% to -$1.2 billion in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$1.2 billion, -$1.1 billion, and -$1.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | EyePoint | 1.25 Bn | 1.07 Bn | 507,000.00 | -1.28 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.28 Bn |
| Mar 31, 2026 | -1.19 Bn |
| Dec 31, 2025 | -1.10 Bn |
| Sep 30, 2025 | -1.04 Bn |
| Jun 30, 2025 | 832,000.00 |
| Mar 31, 2025 | -918.21 Mn |
| Dec 31, 2024 | 1.03 Mn |
| Sep 30, 2024 | 1.17 Mn |
| Jun 30, 2024 | -802.26 Mn |
| Mar 31, 2024 | -771.43 Mn |
| Dec 31, 2023 | 864,000.00 |
| Sep 30, 2023 | -728.05 Mn |
| Jun 30, 2023 | -715.44 Mn |
| Mar 31, 2023 | -692.52 Mn |
| Dec 31, 2022 | 786,000.00 |
| Sep 30, 2022 | 653,000.00 |
| Jun 30, 2022 | -609.48 Mn |
| Mar 31, 2022 | -590.07 Mn |
| Dec 31, 2021 | -569.10 Mn |
| Sep 30, 2021 | 841,000.00 |